Clear Gene

Cover Block

Attribute	Detail
Name	Clear Gene
Tagline	Specializes in RNA diagnostics, developing molecular diagnostic tests for cancer and COVID.
Headquarters	San Carlos, California
Founded	2012
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale

Links

• Website: https://cleargene.com
• LinkedIn: https://www.linkedin.com/company/clear-gene

What an Investor Needs First

Clear Gene is a San Carlos-based biotech company, founded in 2012, that develops RNA-based molecular diagnostic tests and cloud software to improve efficiency in clinical laboratories. The company warrants investor attention for its dual focus on a high-value, persistent oncology market and its demonstrated ability to pivot its RNA diagnostic platform to address acute public health needs, specifically the COVID-19 pandemic [LinkedIn, retrieved 2024]. Its core proposition is to help labs process more samples at lower cost by layering cloud-based data science on top of existing PCR equipment, a capital-efficient wedge into a traditionally hardware-intensive sector [cleargene.com, retrieved 2024].

Public sources confirm the company's ongoing activity and a small team size, estimated at between two and ten employees [LinkedIn, retrieved 2024]. Its business model appears to be B2B, targeting clinical labs with diagnostic tests and software-as-a-service tools, though specific pricing, customer names, and revenue figures are not disclosed.

Over the next 12 to 18 months, key monitors will be any public disclosure of funding, which would signal external validation and growth capital, and the emergence of named commercial partnerships or customer deployments that move beyond general claims. The company's mention of a drug pipeline in a secondary source also suggests a potential, though unconfirmed, expansion into therapeutics, which would represent a significant strategic shift [Synapse, retrieved 2026].

Data Accuracy: YELLOW -- Core company description is confirmed by primary sources; key operational and financial details are absent or unverified.

Taxonomy Snapshot

Axis	Value
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale

Inside the Company

Clear Gene, Inc. was founded in 2012 and maintains its headquarters in San Carlos, California [LinkedIn, retrieved 2024]. The company's public narrative describes a focus on RNA diagnostics that predates the COVID-19 pandemic, initially combining data science with molecular assays to improve cancer testing [LinkedIn, retrieved 2024]. Its pivot to developing a rapid COVID-19 test for clinical labs, and the accompanying cloud-based software to analyze results from existing PCR equipment, represents a significant operational milestone cited in its own materials [LinkedIn, retrieved 2024].

Key personnel are not visible in public records beyond a single named scientist, Dominique Piché, listed as a Senior Scientist [Crunchbase, retrieved 2024]. Employee estimates place the team size between two and ten individuals [LinkedIn, retrieved 2024][Prospeo, retrieved 2024].

Data Accuracy: YELLOW -- Core facts (founding year, HQ, product focus) are confirmed by the company's own pages. Team size is estimated from directory listings, and founder identities are not publicly available.

Under the Hood

Clear Gene’s public-facing proposition centers on a specific wedge in molecular diagnostics: applying software and data science to RNA-based tests, allowing clinical labs to extract more value from their existing PCR instruments. The company describes its work as developing "molecular diagnostic tests for RNA, from cancer to COVID" [cleargene.com, retrieved 2024]. Its narrative suggests a pivot in focus, not technology, having combined data science with molecular assays to improve cancer diagnostics before the pandemic, then developing a rapid COVID-19 test for labs when demand shifted [LinkedIn, retrieved 2024].

The core technical offering appears to be a cloud-based software layer. The company states it repurposed this software to help labs analyze results from existing PCR instruments "without local software installation delays" [LinkedIn, retrieved 2024]. The claimed benefit is operational efficiency: helping labs "process more samples, for less cost, using existing equipment" [cleargene.com, retrieved 2024]. A separate source notes a "drug pipeline and therapeutic area focus" [Synapse, retrieved 2026], but this claim lacks public corroboration.

Data Accuracy: YELLOW -- Product claims are sourced from the company's own website and LinkedIn, but technical specifications, performance data, and customer deployment details are not publicly available.

Market Research

The market for RNA-based diagnostics is expanding beyond its pandemic-era focus, driven by a persistent need for clinical lab efficiency and the growing recognition of RNA's role in chronic disease management. Clear Gene's positioning at the intersection of molecular biology and cloud-based data analysis places it within a specialized but increasingly relevant segment of the broader diagnostics industry.

The company's focus on clinical lab workflow improvement aligns with the larger, adjacent market for clinical laboratory services, which was valued at approximately $274.7 billion globally in 2022 [Grand View Research, 2023]. The more specific molecular diagnostics market was reported at $25.8 billion in 2023 [Precedence Research, 2024].

Key demand drivers for this segment include the ongoing need for cost containment in healthcare and the push for lab automation. The company's stated goal is to help labs "process more samples, for less cost, using existing equipment" [cleargene.com, retrieved 2024], a value proposition that responds directly to margin pressure in clinical operations.

Data Accuracy: YELLOW -- Market sizing is drawn from analogous, broader industry reports; specific TAM for RNA diagnostic tools is not confirmed.

Competition and Substitutes

Clear Gene operates in a specialized niche, applying software to RNA-based molecular diagnostics for clinical labs.

• Incumbent diagnostic giants. Companies like Roche, Abbott Laboratories, and Qiagen dominate the market for centralized lab instruments and FDA-approved diagnostic assays. Clear Gene's approach of software to augment existing PCR instruments suggests a strategy of compatibility rather than displacement.
• Specialized oncology diagnostics players. Firms such as Guardant Health and Exact Sciences have built substantial businesses on proprietary assays. Clear Gene's stated early work on improving cancer tests via RNA and data science places it in an adjacent, but distinct, technical space.
• COVID-19 testing entrants. Clear Gene's development of a rapid COVID-19 test for labs entered a crowded segment. Its differentiator was cloud-based software to speed analysis on existing hardware.
• Adjacent software and data science providers. Companies like DNAnexus or Benchling offer cloud platforms for genomic data management and lab workflow. Clear Gene's combination of a specific diagnostic focus with its own cloud software suggests a more integrated product vision.

Where Clear Gene claims a defensible edge is in its specific integration of data science with RNA molecular assays for the clinical lab setting [cleargene.com, retrieved 2024] [LinkedIn, retrieved 2024]. The durability of this edge is questionable without visible commercial traction, patent protection, or proprietary data moats.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's described focus areas and standard industry segments; no direct competitor names or comparative metrics are publicly confirmed.

Opportunity

The potential outcome for Clear Gene is to become a specialized, software-enabled provider of RNA diagnostic tools that clinical labs adopt as a standard component of their testing workflows, particularly for complex conditions like cancer.

Scenario	What happens	Catalyst	Why it's plausible
Standardization in a Niche Oncology Panel	A specific RNA-based cancer test gains clinical validation and is adopted by a network of regional labs.	Publication of a peer-reviewed study demonstrating superior clinical utility.	The company's foundational work combined data science and molecular assays to improve cancer tests [LinkedIn, retrieved 2024].
Cloud Software as a Lab Operating System	The cloud-based analysis platform becomes the default software layer for labs running a variety of PCR tests.	A partnership with a major PCR instrument manufacturer to bundle or recommend the software.	The software was designed to help labs analyze results from existing instruments without local installation delays [LinkedIn, retrieved 2024].

Data Accuracy: YELLOW -- The opportunity analysis is built on the company's stated capabilities and historical pivots, but lacks corroborating evidence from customer deployments or commercial partnerships.

Sources

1. [LinkedIn, retrieved 2024] Clear Gene | LinkedIn, https://www.linkedin.com/company/clear-gene
2. [cleargene.com, retrieved 2024] Jobs - Clear Gene, https://cleargene.com/jobs
3. [cleargene.com, retrieved 2024] Clear Gene, Inc., https://cleargene.com/
4. [Crunchbase, retrieved 2024] Dominique Piché - Crunchbase Person Profile, https://www.crunchbase.com/person/dominique-pich%C3%A9
5. [Prospeo, retrieved 2024] Clear Gene - Prospeo directory, https://prospeo.io/c/clear-gene
6. [Synapse, retrieved 2026] Clear Gene, Inc. - Drug pipelines, Patents, Clinical trials - Synapse, https://synapse.patsnap.com/organization/5bf0d6dc853dd5dad97caebde91fc167
7. [Grand View Research, 2023] Clinical Laboratory Services Market Size Report, 2023-2030, https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-services-market
8. [Precedence Research, 2024] Molecular Diagnostics Market Size, Share, Growth Report 2024-2033, https://www.precedenceresearch.com/molecular-diagnostics-market